Loading...
•
Jun 30, 2021
Enanta Pharmaceuticals Q3 2021 Earnings Report
Reported financial results for the fiscal third quarter ended June 30, 2021.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $21.6 million for the quarter ended June 30, 2021, primarily from royalty revenue. The net loss was $24.0 million, or $1.19 per diluted common share. Cash, cash equivalents, and marketable securities totaled $372.5 million at the end of the quarter.
Nominated EDP-235, an oral protease inhibitor for COVID-19 treatment, with Phase 1 study planned for early Q1 2022.
On track to dose first subject in Phase 1 study of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer.
Reported positive preliminary data from Phase 1b study of EDP-514 in viremic chronic HBV patients, showing a mean reduction of 3.3 logs in HBV DNA.
Royalty revenue for the quarter was $21.6 million.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and short-term and long-term marketable securities, as well as its continuing royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs for at least the next two years.